Allan E. Rubenstein, MD, is Clinical Professor of Neurology and Pediatrics at NYU Langone Medical Center, New York. Dr. Rubenstein has spent most of his career in research on neurofibromatosis (NF) and related genetic disorders. Dr. Rubenstein founded the National NF Foundation (now Children's Tumor Foundation) in 1978, and from 1978 until 2003 he served as its Director of Medical Affairs. Currently he serves as Medical Director Emeritus.
Dr. Rubenstein has authored several books on NF and has been a consultant to the NIH, FDA Orphan Drugs Program and the U.S. Department of Defense NF Research Program, where, from 2001 to 2002, he was Chairman of its Integration Panel. Since 1992 Dr. Rubenstein has served as Chairman and subsequently as Vice-Chairman and lead director of the Board of Directors of The Cooper Companies (COO, NYSE), a medical device company. He was also a member from 2000-2003 of the Board of Directors of Bioimaging Technologies (BITI, NASDAQ), a clinical research organization.
Allen B. Salmasi is Chairman of the Board, Chief Executive Officer and President of NextWave Wireless and NextWave Broadband. Previously, Mr. Salmasi served as Chairman and CEO of NextWave Telecom, which he founded in 1995 and subsequently sold to Verizon Wireless in 2005.
Prior to NextWave Telecom, Mr. Salmasi was a member of the Board of Directors, President of the Wireless Telecommunications Division, and Chief Strategic Officer of QUALCOMM Inc. He joined QUALCOMM in 1988 as a result of the merger of QUALCOMM and Omninet Corporation, which Mr. Salmasi founded in 1984. He initiated and led the development of CDMA cellular and PCS technologies and the associated businesses at QUALCOMM until 1995. At Omninet, among other technologies, Mr. Salmasi led the development and the operation of the OmniTRACS system and service, the world's first and currently the largest commercial mobile satellite communications service. From 1979 to 1984, Mr. Salmasi held several technical and management positions at the National Aeronautics and Space Administration Jet Propulsion Laboratory.
Mr. Salmasi received two B.S. degrees in Electrical Engineering and Management Economics from Purdue University in 1977. He received his M.S. degrees in Electrical Engineering from Purdue University in 1979 and Applied Mathematics from the University of Southern California in 1983, respectively. He completed his course work at the University of Southern California towards a Ph.D. degree in Electrical Engineering.
Hen Suh Park, PhD has been the Chairman and CEO of Korea Information & Communications Co., Ltd., Seoul, Korea since 1996. Dr. Park founded the company in 1986, which now runs the nations largest network of electronic card authorization systems. Prior to that, he was the Senior Vice President of Oriental Telecommunication, Co. Ltd. from 1983-1986. He has been an invited Professor at Korea University and was the Acting President of Korea Institute of Technology in 1982. Dr. Park is a second term University Council Member of Cornell University (1998 - 2002) and the Recipient of the Prize for New Technology & Management (1997). He is also Vice-Chairman of the Korea Information Protection and Security Association (1996 - Present). Dr. Park served as President of the Cornell Club Korea (1995 - 1997) and was elected to be a Member of the Cornell University Council (1994 - 1997). Dr. Park is a recipient of the Republic of Korea National Medal for Industrial Service Merit (1993) that is awarded by the President of Korea for contributing to the promotion of Science Technologies in Korean Telecommunications Industry. He holds a Ph.D. in electrical engineering from Cornell University.
Mauro Geller, MD, PhDis a Professor and Chairman of Microbiology and Immunology at the Medical School of Fundação Educacional Serra dos Orgãos in Rio de Janeiro, Brazil and is head of the Genodermatosis Unit at the Federal University of Rio de Janeiro. Dr. Geller has been a Member of the Board of Directors of the International Neurofibromatosis Foundation since 1992. In 2004, he published a book on NF in Portuguese that will also be published in Spanish. From 1986 to 1994, Dr. Geller was Medical Director at Farmitalia and Pharmacia laboratories. In addition, he worked in similar capacities for Laboratorio Espasil Delagrange from 1980 to 1986 and for Parke-Davis from 1978 to 1979. Dr. Geller was the originator of the buyout of Carlo Erba in 1994 (Farmitalia and Pharmacia were the predecessors to Carlo Erba) and the Company's Technical Director from 1995-1996. Since 2003, Dr. Geller has been the Latin American representative for Ethypharm Industries, for the registration, research and development of new products in Latin America. Dr. Geller has published 180 scientific papers and four books, and has been a Fellow of the American College of Physicians since 1997, as well as a member of the ACP Scientific Committee, Brazil region, since 1998.
Back to top